Oramed Pharmaceuticals (ORMP) Long-Term Deferred Tax (2019 - 2023)

Oramed Pharmaceuticals' Long-Term Deferred Tax history runs 5 years deep, the most recent figure standing at $27.8 million for Q4 2023.

• Quarterly Long-Term Deferred Tax rose 0.53% year-over-year to $27.8 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $27.8 million (up 0.53% YoY) and the FY2023 annual result came in at $27.8 million, up 0.53% from the prior year.
• Long-Term Deferred Tax was $27.8 million for Q4 2023 at Oramed Pharmaceuticals, up from $27.6 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $27.8 million in Q4 2023 and bottomed at $13.2 million in Q3 2019.
• A 5-year average of $21.3 million and a median of $21.2 million in 2021 frame the typical range for Long-Term Deferred Tax.
• Annual changes were most pronounced in 2021 — Long-Term Deferred Tax gained 27.29% — and 2023, when it climbed 0.53%.
• Oramed Pharmaceuticals' Long-Term Deferred Tax stood at $13.2 million in 2019, then rose by 25.78% to $16.7 million in 2020, then gained by 27.29% to $21.2 million in 2021, then surged by 30.26% to $27.6 million in 2022, then grew by 0.53% to $27.8 million in 2023.
• Business Quant data shows ORMP's Long-Term Deferred Tax at $27.8 million in Q4 2023, $27.6 million in Q4 2022, and $21.2 million in Q3 2021.